Loss of 14-3-3σ in Prostate Cancer and Its Precursors

Clinical Cancer Research

Volumn 10, Issue 9, 2004, Pages 3064-3068

  Cheng, Liang ^a,d   Pan, Chong Xian ^b   Zhang, Jian Ting ^a   Zhang, Shaobo ^a   Kinch, Michael S ^c   Li, Lang ^a   Baldridge, Lee Ann ^a   Wade, Christopher ^a   Hu, Zhiqiang ^a   Koch, Michael O ^a   Ulbright, Thomas M ^a   Eble, John N ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MEDIMMUNE   (United States)

^d INDIANA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

14 3 3 DELTA ANTIBODY; 14 3 3 DELTA PROTEIN; ISOPROTEIN; POLYCLONAL ANTIBODY; PROTEIN 14 3 3; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER INVASION; CARCINOGENESIS; CARCINOMA IN SITU; CELL CYCLE G2 PHASE; CELL TYPE; CHROMOSOME ABERRATION; CONTROLLED STUDY; CORRELATION ANALYSIS; EARLY CANCER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MITOSIS INHIBITION; PRECANCER; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROTEIN FAMILY; PROTEIN FUNCTION;

ADENOCARCINOMA; ADULT; AGED; EXONUCLEASES; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 2442551761     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-03-0652     Document Type: Article

References (22)

1. Wang W, Shakes DC. Molecular evolution of the 14-3-3 protein family. J Mol Evol 1996;43:384-98.
2. Rosenquist M, Sehnke P, Ferl RJ, Sommarin M, Larsson C. Evolution of the 14-3-3 protein family: does the large number of isoforms in multicellular organisms reflect functional specificity? J Mol Evol 2000; 51:446-58.
3. Leffers H, Madsen P, Rasmussen HH, et al. Molecular cloning and expression of the transformation sensitive epithelial marker stratifin. A member of a protein family that has been involved in the protein kinase C signalling pathway. J Mol Biol 1993;231:982-98.
4. Vellucci VF, Germino FJ, Reiss M. Cloning of putative growth regulatory genes from primary human keratinocytes by subtractive hybridization. Gene 1995;166:213-20.
5. Prasad GL, Valverius EM, McDuffie E, Cooper HL. Complementary DNA cloning of a novel epithelial cell marker protein, HME1, that may be down-regulated in neoplastic mammary cells. Cell Growth Differ 1992;3:507-13.
6. 2/M progression. Mol Cell 1997;1:3-11.
7. Chan TA, Hermeking H, Lengauer C, Kinzler KW, Vogelstein B. 14-3-3σ is required to prevent mitotic catastrophe after DNA damage. Nature (Lond) 1999;401:616-20.
8. Dellambra E, Patrone M, Sparatore B, et al. Stratifin, a keratinocyte specific 14-3-3 protein, harbors a pleckstrin homology (PH) domain and enhances protein kinase C activity. J Cell Sci 1995;108:3569-79.
9. Iwata N, Yamamoto H, Sasaki S, et al. Frequent hypermethylation of CpG islands and loss of expression of the 14-3-3σ gene in human hepatocellular carcinoma. Oncogene 2000;19:5298-302.
10. Osada H, Tatematsu Y, Yatabe Y, et al. Frequent and histological type-specific inactivation of 14-3-3σ in human lung cancers. Oncogene 2002;21:2418-24.
11. Suzuki H, Itoh F, Toyota M, Kikuchi T, Kakiuchi H, Imai K. Inactivation of the 14-3-3σ gene is associated with 5′ CpG island hypermethylation in human cancers. Cancer Res 2000;60:4353-7.
12. Umbricht CB, Evron E, Gabrielson E, Ferguson A, Marks J, Sukumar S. Hypermethylation of 14-3-3σ (stratifin) is an early event in breast cancer. Oncogene 2001;20:3348-53.
13. Ferguson AT, Evron E, Umbricht CB, et al. High frequency of hypermethylation at the 14-3-3σ locus leads to gene silencing in breast cancer. Proc Natl Acad Sci USA 2000;97:6049-54.
14. Gleason DF, Mellinger GT. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 1974;111:58-64.
15. Fleming I, Cooper J, Henson D, et al. AJCC cancer staging manual. Philadelphia: Raven and Lippincott, 1997.
16. Cheng L, Nagabhushan M, Pretlow TP, Amini SB, Pretlow TG. Expression of E-cadherin in primary and metastatic prostate cancer. Am J Pathol 1996;148:1375-80.
17. Jiang J, Neubauer BL, Graff JR, et al. Expression of group IIA secretory phospholipase A2 is elevated in prostatic intraepithelial neoplasia and adenocarcinoma. Am J Pathol 2002;160:667-71,
18. Zeng G, Hu Z, Kinch MS, et al. High-level expression of EphA2 receptor tyrosine kinase in prostatic intraepithelial neoplasia. Am J Pathol 2003;163:2271-6.
19. Cheng L, Song SY, Pretlow TG, et al. Evidence of independent origin of multiple tumors from patients with prostate cancer. J Natl Cancer Inst (Bethesda) 1998;90:233-7.
20. Cheng L, Bostwick DG, Li G, et al. Allelic imbalance in the clonal evolution of prostate carcinoma. Cancer (Phila) 1999;85:2017-22.
21. Cheng L, Bergstralh EJ, Slezak J, Cheville JC, Zincke H, Bostwick DG. Dedifferentiation in metastatic progression of prostate cancer. Cancer (Phila) 1999;86:657-63.
22. Cheng L, Zincke H, Blute ML, Bergstralh EJ, Scherer B, Bostwick DG. Risk of prostate caricnoma death in patients with lymph node metastasis. Cancer (Phila) 2001;66-73.